Aardvark Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AARD and other ETFs, options, and stocks.

About AARD

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. 

CEO
Tien Li Lee
CEOTien Li Lee
Employees
40
Employees40
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2017
Founded2017
Employees
40
Employees40

AARD Key Statistics

Market cap
31.73M
Market cap31.73M
Price-Earnings ratio
-1.23
Price-Earnings ratio-1.23
Dividend yield
—
Dividend yield—
Average volume
258.73K
Average volume258.73K
High today
$4.95
High today$4.95
Low today
$1.36
Low today$1.36
Open price
$2.99
Open price$2.99
Volume
16.29M
Volume16.29M
52 Week high
$16.60
52 Week high$16.60
52 Week low
$1.36
52 Week low$1.36

Stock Snapshot

Aardvark Therapeutics(AARD) stock is priced at $1.42, giving the company a market capitalization of 31.73M. It carries a P/E multiple of -1.23.

During the trading session on 2026-10-23, Aardvark Therapeutics(AARD) shares reached a daily high of $4.95 and a low of $1.36. At a current price of $1.42, the stock is +4.8% higher than the low and still -71.3% under the high.

Trading volume for Aardvark Therapeutics(AARD) stock has reached 16.29M, versus its average volume of 258.73K.

The stock's 52-week range extends from a low of $1.36 to a high of $16.60.

The stock's 52-week range extends from a low of $1.36 to a high of $16.60.

AARD News

Benzinga 7h
Why Is Aardvark Therapeutics Stock Trading Lower Today? - Aardvark Therapeutics - Benzinga

...

Why Is Aardvark Therapeutics Stock Trading Lower Today? - Aardvark Therapeutics - Benzinga
Benzinga 7h
Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient

Aardvark Therapeutics Inc. (NASDAQ:AARD) stock plunged on Friday after the release of exploratory efficacy data from its terminated Phase 3 HERO trial and open-...

Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient
TipRanks 10h
Aardvark Therapeutics advances ARD-101 after FDA hold lift

Aardvark Therapeutics, Inc. ( (AARD) ) has provided an announcement. On October 23, 2026, Aardvark Therapeutics reported exploratory efficacy and safety data f...

Analyst ratings

50%

of 10 ratings
Buy
50%
Hold
30%
Sell
20%

More AARD News

TipRanks 12h
Aardvark Therapeutics reports exploratory efficacy data from HERO trial

Aardvark Therapeutics (AARD) reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective, or HERO, trial...

People also own

Based on the portfolios of people who own AARD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.